GLPG

Galapagos NV ADR

GLPG, USA

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

https://www.glpg.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GLPG
stock
GLPG

Did Strong GLPG5101 CAR T Data and Decentralized Manufacturing Just Shift Galapagos' (ENXTAM:GLPG) Investment Narrative? simplywall.st

Read more →
GLPG
stock
GLPG

Analyst Downgrade: Can TOPW stock deliver 10 annual returns - Weekly Risk Report & Fast Gain Swing Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$27.4857

Analyst Picks

Strong Buy

0

Buy

0

Hold

4

Sell

1

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.71

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-7.03 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-4.90 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-91.98 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.44

Low 1

High 0.3

Investors

* Institutions hold a combined 23.69% of the total shares of Galapagos NV ADR

1.

TANG CAPITAL MANAGEMENT LLC

(6.0551%)

since

2025/06/30

2.

Madison Avenue Partners, LP

(2.8484%)

since

2025/06/30

3.

Prosight Management, LP

(2.6915%)

since

2025/06/30

4.

FMR Inc

(2.3476%)

since

2025/06/30

5.

EcoR1 Capital, LLC

(1.5736%)

since

2025/06/30

6.

Hudson Bay Capital Management LP

(0.7815%)

since

2025/06/30

7.

Segall Bryant & Hamill

(0.7604%)

since

2025/06/30

8.

Renaissance Technologies Corp

(0.7052%)

since

2025/06/30

9.

Fidelity Advisor Equity Growth I

(0.6546%)

since

2025/07/31

10.

Fidelity VIP Growth Initial

(0.6005%)

since

2025/07/31

11.

Point72 Asset Management, L.P.

(0.5182%)

since

2025/06/30

12.

UBS Group AG

(0.362%)

since

2025/06/30

13.

Fidelity Growth Discovery

(0.3484%)

since

2025/07/31

14.

BlackRock Inc

(0.343%)

since

2025/06/30

15.

Millennium Management LLC

(0.2894%)

since

2025/06/30

16.

iShares Biotechnology ETF

(0.2827%)

since

2025/08/31

17.

Columbia VP Overseas Core 3

(0.2736%)

since

2025/07/31

18.

D. E. Shaw & Co LP

(0.2325%)

since

2025/06/30

19.

PRIMECAP Management Company

(0.2175%)

since

2025/06/30

20.

Dafna Capital Management LLC

(0.1975%)

since

2025/06/30

21.

NORGES BANK

(0.1821%)

since

2025/06/30

22.

Segall Bryant & Hamill Sm Cp Val Ins

(0.1723%)

since

2025/07/31

23.

PRIMECAP Odyssey Aggressive Growth

(0.1514%)

since

2025/06/30

24.

Centiva Capital LP

(0.144%)

since

2025/06/30

25.

VOLORIDGE INVESTMENT MANAGEMENT, LLC

(0.1296%)

since

2025/06/30

26.

Royal Bank of Canada

(0.1227%)

since

2025/06/30

27.

Tower Research Capital LLC

(0.1201%)

since

2025/06/30

28.

VP Partners Small Cap Value 3

(0.0738%)

since

2025/07/31

29.

Pacific Select Large-Cap Growth I

(0.0735%)

since

2025/08/31

30.

Columbia Overseas Core Institutional 3

(0.0706%)

since

2025/07/31

31.

Steward Values Enhanced International I

(0.0705%)

since

2025/07/31

32.

Fidelity Advisor Series Equity Gr

(0.0677%)

since

2025/07/31

33.

Vanguard US Opportunities Ins USD Acc

(0.066%)

since

2025/06/30

34.

ALPS Medical Breakthroughs ETF

(0.0471%)

since

2025/08/29

35.

Avantis International Equity ETF

(0.0311%)

since

2025/08/30

36.

ERSTE STOCK BIOTEC EUR R01 A

(0.0212%)

since

2025/07/31

37.

ActivePassive International Equity ETF

(0.0209%)

since

2025/08/29

38.

Fidelity Equity Growth K6

(0.0136%)

since

2025/07/31

39.

iShares Nasdaq US Biotech ETF USD Acc

(0.0127%)

since

2025/08/31

40.

Barometer Global Equity Fund A

(0.0123%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1904

Latest Release

Date

2025-09-30

EPS Actual

-3.54

EPS Estimate

-0.3529

EPS Difference

-3.1871

Surprise Percent

-903.117%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(5.5)
Net Net
Possible Net-Net(4.5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.